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A B S T R A C T
Background
Many palliative care patients have a reduced oral intake during their illness. The management of this can include the provision of
medically assisted nutrition with the aim of prolonging the length of life of a patient, improving their quality of life, or both.
Objectives
To determine the effect of medically assisted nutrition on the quality and length of life of palliative care patients.
Search methods
Studies were identified from searching The Cochrane Library, MEDLINE (1966 to 2008), EMBASE (1980 to 2008), CINAHL,
CANCERLIT, Caresearch, Dissertation abstracts, SCIENCE CITATION INDEX and the reference lists of all eligible trials, key
textbooks, and previous systematic reviews. The date of the latest search was July 2008.
Selection criteria
All relevant randomised controlled trials (RCTs) or prospective controlled trials (if no RCTs were found).
Data collection and analysis
There were no RCTs or prospectively controlled trials found that met the inclusion criteria.
Main results
There were four prospective non-controlled trials (including one qualitative study) that studied medically assisted nutrition in palliative
care participants, and one Cochrane systematic review (on Motor Neurone disease), but no RCTs or prospective controlled studies.
Authors’ conclusions
There are insufficient good quality trials to make any recommendations for practice with regards to the use of medically assisted
nutrition in palliative care patients.
P L A I N L A N G U A G E S U M M A R Y
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Medically assisted nutrition to assist palliative care patients
It is common for palliative care patients to have reduced oral intake during their illness. Management of this condition includes
discussion with the patient, family and staff involved and may include giving nutrition with medical assistance. This can be done either
via a plastic tube inserted into a vein directly or into the stomach or other parts of the gastrointestinal tract. It is unknown whether
this treatment helps people to feel better or live longer. A search of the international literature was only able to find a small number of
studies looking at this issue. As a result, it is not possible to clearly define the benefits and harms of this treatment.
B A C K G R O U N D
Many palliative care patients have a reduced oral intake during
their illness. The cause of this varies, but may be part of a phys-
ical obstruction, anorexia/cachexia syndrome, generalised weak-
ness, bowel obstruction, loss of desire to drink or no specific cause
may be identified. The most common time for this decreased oral
intake is during the terminal phase, when the patient becomes less
conscious and therefore less able to receive nutrition orally (Morita
1998).
Management of this condition includes discussion with the pa-
tient, family and staff involved and either no medical intervention
(but continued attention to treating any symptomatic problems,
including good mouth care) or the provision of nutrition with
medical assistance. The aim of this intervention can be to prolong
the length of life of a participant, improve their quality of life, or
both. These benefits may come via the reversal of the physiological
factors associated with the patient’s decline. Balanced against these
potential benefits are adverse events that can be associated with
any intervention (infection, bleeding, pain etc) (Bozzetti 1996). It
is also essential to assess the psycho-spiritual impact of undergoing
the treatment and what their expectations of medically assisted
nutrition are.
Medically assisted nutrition can be performed via a tube inserted
into any part of the gastrointestinal system (enteral) or via a tube
inserted into the venous system (parenteral). There is some con-
troversy and views vary on the ethics of medically assisted nutri-
tion (Casarett 2005). The first ethical controversy centres around
whether medically assisted nutrition is a medical intervention or a
basic provision of comfort. Secondly there is controversy as to how
and by whom should decisions be made with regards to medically
assisted nutrition in patients who no longer have the capacity to
make decisions for themselves. This review will concentrate on
assessing the benefit of provision of nutrition with medical assis-
tance versus the harm caused by such intervention in palliative
care patients. It is only with this information that clinicians and
patients can make informed decisions about whether this type of
intervention is beneficial or harmful to an individual patient.
A separate Cochrane review has been conducted looking at the
provision ofmedically assisted hydration for palliative care patients
(Good 2008).
O B J E C T I V E S
The objectives of this review are to determine the effect of med-
ically assisted nutrition in palliative care patients on their quality
and length of life.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All relevant randomised controlled studies (RCTs) or prospective
controlled studies (if no RCTs were found).
Types of participants
Participants included:
• palliative care participants who received medically assisted
nutrition;
• those that were receiving palliative care (WHO 2005);
• (but not be limited to) incurable cancer, dementia,
neurodegenerative diseases (e.g. Motor Neuron Disease), Human
Immunodeficiency Virus, Chronic Airways Limitation and
Chronic Heart Failure whose prognosis was limited and the
focus of care was quality of life (Doyle 2004;
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• adult participants aged 18 years and above were included,
both male and female and in any setting such as home, hospice
or hospital.
Included participants were not limited to those in the terminal
phase of their illness. Participants who were having medically as-
sisted nutrition as part of a perioperative, chemotherapy or ra-
diotherapy regime, or because of chemotherapy or radiotherapy
adverse effects will be excluded.
Types of interventions
Medically assisted administration of nutrition:
• parenteral nutrition - administration of nutritional liquid
via a central or peripheral venous catheter, that does not directly
enter the gastrointestinal system;
• enteral nutrition - administration of nutritional liquid
through a tube via the gastrointestinal system (nasogastric tube,
jejunostomy, gastrostomy).
Comparisons:
• placebo,
• no intervention,
• usual treatment or supportive care.
Types of outcome measures
Primary outcomes
1. Quality of life on any measure (including symptom
assessment scales)
Secondary outcomes
1. Survival
2. Adverse Events
Search methods for identification of studies
A. Electronic Databases
The following electronic databases were searched using a search
strategy developed forMEDLINE, but modified appropriately for
each database:
• The Cochrane Library: Cochrane Controlled Trials Register,
Cochrane Database of Systematic Reviews, Cochrane Database
of Reviews of Effectiveness.
• MEDLINE (1966 to present).
• EMBASE (1980 to present).
• CINAHL.
• CANCERLIT.
• Caresearch - database listing conference proceedings and
grey literature.
• Dissertation abstracts.
• SCIENCE CITATION INDEX.
Date of most recent search: July 2008
B. Reference Lists
The reference lists of all eligible trials, key textbooks, and previous
systematic reviews were searched for additional studies.
C. Language
The search attempted to identify all relevant studies irrespective
of language. There were no non-English papers identified.
The subject search used a combination of controlled vocabulary
and free text terms based on the search strategy for searchingMED-
LINE. Please see Appendix 1.
This search strategy was adapted for other databases searched.
Data collection and analysis
Studies identified by the search strategy had the title and abstract
(where possible) assessed by the lead review author (PG) to identify
potentially relevant articles.
The results of studies identified from the different databases were
as follows:
The Cochrane Library - 1136 (476 from clinical trials)
MEDLINE - 6655
EMBASE - 4548
CINAHL - 56
CANCERLIT - 2480
Caresearch - 172
Dissertation abstracts - 54
SCIENCE CITATION INDEX - 4601
After review of the title and abstracts, 22 references were retrieved
in full. Unfortunately none of these met the inclusion criteria.
However, there were four prospective non-controlled trials (in-
cluding one qualitative study), and a Cochrane systematic review.
These studies will be described in the discussion section.
Quality
All studies were to have their methodological quality assessed.
There was to be two scales used.
1. RCTs would be assessed via the Oxford Quality Scale
devised by Jadad et al (Jadad 1996).
2. The quality of non RCTs would be assessed using a scale
devised by Rinck et al (Rinck 1997).
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Data extraction
The following information was planned to be obtained for each
study:
• study methods (study design, allocation, blinding, setting,
inclusion criteria);
• participants (sample size, exclusions/inclusions, number,
disease, duration of trial, withdrawals and dropouts, site - e.g.
hospital, hospice, home);
• intervention (type, route of delivery, control used);
• outcome (quality of life, symptom measures, survival, time
from death intervention was initiated);
• adverse effects.
The extraction was to occur independently by two review authors.
Data analysis
The overall effectiveness ofmedically assisted nutrition inpalliative
care participants was to be assessed and also specific sub-group
analysis (where possible) was to be undertaken by:
• study design:
data from RCTs and prospective controlled studies were to be
evaluated separately
• participants:
◦ cancer,
◦ non-cancer,
◦ dementia,
◦ neurodegenerative diseases.
• intervention:
◦ medically assisted nutrition - parenteral, enteral
nutrition.
• study quality
• timing of intervention (in relation to death)
• site
Statistical analysis
No studies were suitable for evaluation.
R E S U L T S
Description of studies
See: Characteristics of excluded studies.
No studies met the inclusion criteria.
Excluded studies
Please see Table 1 in ’Additional tables’ and the Characteristics of
excluded studies table.
Risk of bias in included studies
No studies were evaluated for methodological quality.
Effects of interventions
There were no RCT nor prospectively controlled trials found that
met the inclusion criteria.
D I S C U S S I O N
The objective of this systematic review was to determine the effec-
tiveness of medically assisted nutrition in palliative care patients
(of all ages) on their quality and length of life. Extensive search-
ing of the literature produced no RCTs nor prospective controlled
trials that fulfilled the inclusion criteria. The discussion will focus
only on prospective trials that were retrieved, as this represents
the next highest study quality design. However, the studies are all
of a low quality because of their design, and therefore caution is
needed in interpreting any of the results.
This search identified four prospective non-controlled trials (in-
cluding one qualitative study) that studied medically assisted nu-
trition in palliative care participants (Bozzetti 2002; Meier 2001;
Orrevall 2005; Pironi 1997), and one Cochrane systematic review
(Langmore 2006). One study (Meier 2001) included participants
with advanced dementia. The other three studies (Bozzetti 2002;
Orrevall 2005; Pironi 1997) included only participants with ad-
vanced cancer. In two studies (Bozzetti 2002; Orrevall 2005) par-
ticipants received only parenteral nutrition, whilst in another two
studies (Langmore 2006; Meier 2001) the included participants
had enteral nutrition. In one study (Pironi 1997) included par-
ticipants had either enteral or parenteral nutrition. The Cochrane
review (Langmore 2006) assessed participants with motor neuron
disease.
Survival wasmeasured in three studies (Bozzetti 2002;Meier 2001;
Pironi 1997) and evaluated in the systematic review (Langmore
2006). Quality of Life (QOL) was used as an outcome measure
in three of the studies (Bozzetti 2002; Langmore 2006; Orrevall
2005). Two studies look at the effect of the interventiononKarnof-
sky Performance Scale (KPS) (Bozzetti 2002; Pironi 1997). Only
one study recorded adverse events of the interventions (Pironi
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1997). The qualitative study analysed the positive and negative
features according to the themes derived from the data (Orrevall
2005).
In a prospective, cohort study of participants with advanced de-
mentia there was no significant difference, in survival, between
those participants with PEG inserted (median 195 days, range
21 to 1405 days), and those without PEG insertion (median 189
days, range four to 1502) (P = 0.9) (Meier 2001). The Cochrane
review had conflicting results, in that three studies found a longer
survival in participants who had a PEG, whilst the other four stud-
ies found no difference. Bozzetti 2002 found that participants on
home parenteral nutrition (HPN) had a median survival of four
months. The mean survival was used when Pironi 1997 looked
at participants on HPN (12.2 weeks) and those on home enteral
nutrition (17.2 weeks). QOL did not improve after PEG insertion
for participants with motor neuron disease (Langmore 2006), nor
at one month in those with advanced cancer (Bozzetti 2002), but
there was a perceived benefit in this area in the qualitative study
(Orrevall 2005). In one study (Bozzetti 2002) the KPS was stable
until a progressive decline at three months prior to death, whilst
another study (Pironi 1997) found that at one month after inter-
vention the KPS was increased in 13 participants, decreased in 19
participants, and was unchanged in 132 participants. The quali-
tative study of advanced cancer participants in Sweden (Orrevall
2005) found that HPN produced positive features including as-
surance that nutrition was being met, and this led to a perceived
benefit on energy, strength and activity. It was also seen as de-
creasing the feeling of “pressure to eat” and more acceptance of
whatever was able to be eaten orally.
Pironi 1997 found that with HEN, there was NG tube blockage/
dislodgment in 0.26 per year of HEN and PEG site infection in
one participant and hub replacement in two participants, whilst
the complications of treatment with HPN (per year of treatment
were catheter sepsis (0.67), DVT (0.16) and metabolic instability
(0.50). This study also attempted to look at the burden of med-
ically assisted nutrition for participants and their families. How-
ever, this was only done as a judgement by nutrition staff, and was
therefore open to a large element of bias. They found that medi-
cally assisted nutrition was well accepted in 124 cases (19 HPN),
with annoyance in 30 cases (seven HPN), and scarcely tolerated
in ten cases (three HPN). The qualitative study (Orrevall 2005)
found that the negative features of HPN were related to physi-
cal symptoms of nausea, vomiting, drowsiness and headache, as
well as HPN placing a restriction on their family life and social
involvement.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There are insufficient good quality studies to make any recom-
mendations for practice with regards to the use of medically as-
sisted nutrition in palliative care patients. Clinicians will need to
make a decision based on the perceived benefits and harms of
medically assisted nutrition in individual patient circumstances,
without the benefit of high quality evidence to guide them. The
uncontrolled prospective studies described would suggest that pa-
tients with a good performance status and medium to long term
prognosis (months to years) may benefit from medically assisted
nutrition. However, the evidence base to support this at the mo-
ment is weak and any intention to use this treatment should be
monitored carefully and ideally fed in to further research.
Implications for research
Trial design
There are very few quality studies that have looked at the question
of medically assisted nutrition in palliative care patients. It may
be difficult to ever do a RCT in this area. The logistics of recruit-
ing participants to any palliative care trial are well known (Rinck
1997) but are especially so with regards to medically assisted nu-
trition. There are two distinct palliative care populations, in which
further trials of the effect of medically assisted nutrition would
be useful. The first is those patients who develop the anorexia/
cachexia syndrome. The second is in those patients who are unable
to swallow, but whose prognosis (from their cancer) would seem
to be longer than their prognosis from the aphagia. The difficulty
in this situation is the reliance on the physicians ability to provide
a prognosis, and this is not always accurate (Glare 2003).
As well as looking at the possibility of RCTs in this area, the ev-
idence base will be improved with at least some prospective con-
trolled trials, and even with more prospective uncontrolled trials.
This may need to be done with innovative designs such as compar-
isons between different centres that have different nutrition prac-
tices or by following up cohorts of participants who are offered
medically assisted nutrition, in whom some proceed and some do
not (as long as the two groups are similar).
Patient groups
The studies in this review did not have well defined patient pop-
ulations. Palliative care is performed in hospital, in-patient pallia-
tive care units and the community. Trials need to be performed
in all these areas to allow external validity (able to be applied to a
similar patients as those seen in a trial) to different palliative care
populations. It would also be helpful to define at what stage of
their illness participants are being given medically assisted nutri-
tion. The reasons and aims of nutrition in the last few days/weeks
of life may be very different to those participants with a longer
prognosis. The prospective prediction of prognosis is difficult, and
it may be better to stratify participants according to performance
status.
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Interventions
Medically administered nutrition can be given by many different
routes. Further trials are needed to determine the optimum route
and dose.
Outcomes
It is important that clinically relevant outcomes are clearly defined
and are the most clinically useful to this situation. In this patient
population this includes energy levels, functional status and overall
quality of life. As well as these, the effect of this intervention on
overall survival needs to be reported. Also important is that adverse
events are well defined so that the risk of treatment can be balanced
against any benefits.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bozzetti 2002 Prospective non-controlled trial.
Langmore 2006 Retrospective case control studies, and prospective cohort studies
Meier 2001 Prospective non-controlled trial.
Orrevall 2005 Prospective non-controlled trial.
Pironi 1997 Prospective non-controlled trial.
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Data on excluded studies
Study ID Methods Participants Interventions Outcomes Notes
Bozzetti 2002 Prospective, observa-
tional study
69 adult cancer par-
ticipants
Six centres in Italy
In-
dications for Home
Parenteral Nutrition
(HPN) were intesti-
nal obstruction (58),
malnutrition (7), not
specified (4)
HPN
External tunnelled
catheters (51 partici-
pants) and porta cath
(18 participants)
Median survival was
four months,
after participants be-
gan HPN
At one month there
was no significant
change from baseline
with regards toQual-
ity of Life (using
Rotterdam symptom
checklist) with 40%
improved, 50% de-
teriorated
and 10% no change)
. The Karnofsky Per-
formance Sta-
tus (KPS) was stable
until progressive de-
cline at three months
prior to death
Langmore 2006 Cochrane systematic
review
Motor neuron dis-
ease
Medically As-
sisted Nutrition (via
enteral tube feeding)
There were no RCTs
found. The review
dis-
cussed seven studies.
Five of these stud-
ies were retrospective
case controlled. Two
were prospective co-
hort studies (Chio
2002 and Mazz-
ini 1995). All seven
studies tested for sur-
vival advantage of
intervention. Three
found a longer sur-
vival in participants
who had a PEG,
whilst the other four
found no difference.
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Table 1. Data on excluded studies (Continued)
Only three studies
looked at nutritional
outcomes and these
suggested
a positive advantage
for those participants
with PEGs. Only
two studies looked
at QOL, and both
failed to show im-
provement in QOL
after PEG insertion
Meier 2001 Prospective, cohort
study.
This was part of a
study looking at in-
creased consultation
versus usual care in
the management of
participants with ad-
vanced dementia
182 eligible partici-
pants - 99 consented
to inclusion in study
The ninety three par-
ticipants were ex-
cluded because of:
- no available surro-
gate decision maker
(40),
- surrogate decision
maker unable to un-
derstand and par-
ticipate in informed
consent (19),
- surrogate decision
maker re-
fused informed con-
sent (five),
- subject imminently
dying or medically
unstable (eight),
- language
barrier (three), fam-
ily conflict (three),
and - transferred/dis-
charged/died (five).
The participants had
been admitted to a
New York hospital
with an acute illness
(Pneumonia or Uri-
nary Tract Infection
(61), dehydration or
metabolic abnormal-
ity (12), Other (26))
Of the 99 study par-
ticipants, 82 had no
feeding tube on ad-
mission (two admit-
ted for inser-
tion of feeding tube)
. Of these 82 partici-
pants, 51 had a PEG
inserted during the
index admission
The median survival
was not significantly
different be-
tween those partici-
pants with PEG in-
serted (median 195
days, range 21 to
1405 days)
, and those without
PEG insertion (me-
dian 189 days, range
four to 1502) (P = 0.
9)
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Table 1. Data on excluded studies (Continued)
Orrevall 2005 Qualitative study 13 participants were
interviewed
and 11 family mem-
bers, during 2000
to 2001, in Sweden.
These were recruited
via advanced home
care teams (AHCTs)
nurses being asked to
contact participants
with advanced can-
cer. Participants con-
tacted were asked to
provide names of rel-
atives who were also
willing to participate
Nine participants re-
ceived partial HPN
and oral intake, two
were on total HPN
and two were ac-
tually weaned from
HPN. The interven-
tion con-
sisted of HPN for at
least two weeks (and
at least three times
per week), with an
AHCT nurse con-
necting and discon-
necting the infusion
each time. Ten of
the participants died
within six months
of the interview, but
eleven lived greater
than three months
The positive features
(according to par-
ticipants and rela-
tives) included assur-
ance that nutrition
was being met, and
this led to a perceived
benefit on Quality of
life, energy, strength
and activity. It was
also seen as decreas-
ing the feeling of
“pressure to eat” and
more acceptance of
whatever was able
to be eaten orally.
The benefits of HPN
were very much re-
lated to the close in-
volvement and fre-
quent visits of the
AHCT nurses.
The negative fea-
tures of HPN were
related to physical
symptoms of nausea,
vomiting, drowsi-
ness and headache.
As well HPN placed
a restriction on the
family life and social
involvement
The selection proto-
col used lends itself
to be a large source of
bias
Pironi 1997 Prospective survey Italian advanced can-
cer patients.
Participants were de-
scribed as having ad-
vanced cancer when
receiving only pallia-
tive care.
Participants were in-
cluded if
they had hypophagia
(oral calorie intake
absent or <50% of
basal energy expen-
diture (Harris-Bene-
dict formula), life ex-
pectancy greater
Themethod of inter-
vention for 135 par-
ticipants with HEN
was using a naso-
gastric tube (50%),
percutaneous endo-
scopic
gastrostomy (18%),
jejunostomy (27%),
and surgical gastros-
tomy (5%). The in-
fusion method was
pump (83%) and via
gravity (17%).
In the 29 partici-
Mean survival was
17.2 weeks for par-
ticipants
on HEN and 12.
2 weeks for partici-
pants on HPN. This
included 47 partic-
ipants (29%) who
survived less than
six weeks. This was
most common in
groups with the pri-
mary tumour out-
side gastrointestinal
tract and head-neck
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Table 1. Data on excluded studies (Continued)
than six weeks, suit-
able participant and
family circumstances
(controlled or absent
pain, no severe vital
organ failure, emo-
tional stability, will-
ingness and ability to
cope with HAN-re-
lated ac-
tivities and suitable
hygienic conditions)
, and able to give ver-
bal consent.
6838 participants on
a hospital-at-
home program - 587
of these referred for
assessment of HAN.
Of these 587, 164
were eligible and re-
ceived HAN - 135
enteral (HEN), 29
parenteral (HPN).
The reasons for ex-
clusion of the 423
partic-
ipants included ab-
sence of hypopha-
gia (264), estimated
life expectancy < 6
weeks, lack of suit-
able home/family
conditions (30) and
lack of consent (21).
50 participants
(30%) aware of their
diagnosis.
pants with HPN the
methods used were
non tunnelled per-
cutaneous catheters
(79%), tun-
nelled percutaneous
catheters (14%) and
totally implanted
ports (7%)
region, and in the
group with a Karnof-
sky Perfor-
mance Score (KPS)
of less than or equal
to 40. During the
first month of HAN
the KPS increased in
13 participants, de-
creased in 19 partic-
ipants, and was un-
changed in 132 par-
tic-
ipants. Twelve par-
ticipants on HEN
became able to go
out and look after
themselves unaided,
whilst two became
housebound. Body
weight increased in
43 participants, de-
creased in 21 par-
ticipants and there
was no change in
80 participants, with
20 participants con-
fined to bed) and un-
able to be weighed.
Of the 108 partic-
ipants excluded be-
cause their estimated
survival was less than
six weeks, 31 (29%)
lived greater than or
equal to six weeks.
During treatment
there were 95 par-
ticipants (61%) who
underwent 155 hos-
pital read-
missions. This in-
cluded three admis-
sions for HPN com-
plications and seven
for jejunostomy po-
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Table 1. Data on excluded studies (Continued)
sitioning.
An attempt
was made to record
the burden to the
participant and fam-
ilies. This was judged
by the nutrition staff,
and was dependent
on the level of com-
plaints of the par-
ticipant and fami-
lies. They found that
HAN was well ac-
cepted in 124 cases
(19 HPN), with an-
noyance in 30 cases
(seven
HPN), and scarcely
tolerated in ten cases
(three HPN).
In terms of compli-
cations
withHEN, there was
NG tube blockage/
dislodgment in 0.26
per year of HEN and
PEG site infection in
one participant and
hub replace-
ment in two partic-
ipants. The compli-
cations of treatment
with HPN (per year
of treatment were
catheter sepsis (0.67)
, DVT (0.16) and
metabolic instability
(0.50)
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A P P E N D I C E S
Appendix 1. Search strategy
#1 MeSH descriptor PALLIATIVE CARE explode all trees
#2 palliat* in All Text
#3 MeSH descriptor TERMINALLY ILL this term only
#4 MeSH descriptor TERMINAL CARE explode all trees
#5 (terminal* in All Text near/6 care* in All Text)
#6 ( (terminal* in All Text near/6 ill* in All Text) or terminal-stage* in All Text or dying in All Text or (close in All Text near/6 death
in All Text) )
#7 (terminal* in All Text near/6 diseas* in All Text)
#8 (end in All Text near/3 life in All Text)
#9 hospice* in All Text
#10 (end-stage next disease* in All Text or end next stage next disease* in All Text or end-stage next illness in All Text or end next stage
next illness in All Text or end-stage next care in All Text or end next stage next care in All Text)
#11 incurable next illness* in All Text
#12 incurable next disease* in All Text
#13 (advanced next directive* in All Text or living next will* in All Text or do-not-resuscitate next order* in All Text)
#14 (end-stage next disease* in All Text or end next stage next disease* in All Text or end-stage next illness in All Text or end next stage
next illness in All Text or end-stage next care in All Text or end next stage next care in All Text)
#15 (advanced in All Text near/6 disease* in All Text)
#16 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15)
#17 MeSH descriptor NUTRITION explode all trees
#18 MeSH descriptor NUTRITION ASSESSMENT explode all trees
#19 MeSH descriptor NUTRITION THERAPY explode all trees
#20 MeSH descriptor FEEDING METHODS explode all trees
#21 (feed in All Text or feeding in All Text or fed* in All Text or food* in All Text)
#22 MeSH descriptor FOOD explode all trees
#23 diet* in All Text
#24 nutrition* in Record Title
#25 nutrition* in Abstract
#26 (#17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25)
#27 (#16 and #26)
WH A T ’ S N E W
Last assessed as up-to-date: 17 July 2008.
Date Event Description
11 May 2011 Amended Contact details updated.
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H I S T O R Y
Protocol first published: Issue 4, 2006
Review first published: Issue 4, 2008
Date Event Description
6 October 2010 Amended Contact details updated.
30 October 2008 Amended Minor edits made to text using new RevMan 5 software
C O N T R I B U T I O N S O F A U T H O R S
Phillip Good: formulate question, write protocol, search for studies, review abstracts, retrieve articles, assess article quality, write review,
write update.
John Cavenagh: formulate question, critical revision of review.
Peter Ravenscroft: formulate question, critical revision of review.
Mark Mather: formulate question, critical revision of review.
D E C L A R A T I O N S O F I N T E R E S T
None known
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Enteral Nutrition [adverse effects; methods]; ∗Parenteral Nutrition [adverse effects; methods]; Longevity; Palliative Care [∗methods];
Quality of Life
MeSH check words
Adult; Humans
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